

Fentora - (EQ 0.1, 0.2, 0.3, 0.4, 0.6, 0.8 mg ; Tablet, Buccal, Sublingual)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | Fentanyl Citrate | Innovator | Cephalon |
| Dosage | EQ 0.1, 0.2, 0.3, 0.4, 0.6, 0.8 mg ; Tablet, Buccal, Sublingual | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | More Than 5 |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | Less Than 5 | Generic Launches | None |
| Indication | Indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.